Skip to main content

Table 3 Longitudinal changes in all efficacy variables from baseline (T0 - trimester before initiation of therapy) over three years of onabotulinumtoxinA (Botox ®) (T3) in 56 patients

From: Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment

Efficacy Variables T0
Mean ± SD
Range
Median
T1
Mean ± SD
Range
Median
T2
Mean ± SD
Range
Median
T3
Mean ± SD
Range
Median
P value
*T1 vs T3
**T2 vs T3
Headache days/month 21.5 ± 5.1
14–30
20
7.2 ± 3.8
2–15
6
5.4 ± 2.6
1–11
5
3.4 ± 1.7
1–11
4
*P < 0.001
**P < 0.001
Number of days with peak headache intensity of more than 4/10 per month 11.7 ± 5.7
4–30
10
3.4 ± 2.8
0–14
3
3.2 ± 1.6
1–7
3
2.5 ± 1.1
1–5
2
*P = 0.052
**P < 0.001
Days with any acute headache medication / month 16.5 ± 7.3
7–30
14
4.7 ± 3.2
0–14
4
3.4 ± 1.7
1–8
3
2.8 ± 1.3
1–7
2
*P < 0.001
**P < 0.001
  1. T0 refers to the trimester before initiation of therapy; τ1 refers to the trimester after the third onabotulinumtoxinA administration, T2 to the trimester after completing two years of treatment and T3 to the trimester after completing three years of treatment
  2. *P values stand for significant changes between T1 vs T3
  3. **P values stand for significant changes between T2 vs T3